Autosomal dominant polycystic kidney disease: Risk factor for nonmelanoma skin cancer following kidney transplantation

Transplant International

Volumn 23, Issue 9, 2010, Pages 878-886

  Bretagnol, Anne ^a   Halimi, Jean Michel ^a   Roland, Mélanie ^a   Barbet, Christelle ^a   MacHet, Laurent ^a   Al Najjar, Azmi ^a   Marlière, Jean Frédéric ^a   Badin, Julie ^a   Nivet, Hubert ^a   Lebranchu, Yvon ^a   Büchler, Matthias ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

polycystic disease; renal transplantation; risk factor; skin cancer

Indexed keywords

ADULT; AGE; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CANCER RISK; FEMALE; GENDER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN CANCER; SUN EXPOSURE;

ADULT; AGE FACTORS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955256264     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01070.x     Document Type: Article

References (24)

1. Bouwes Bavinck J, Hardie D, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996 61 : 715.
2. Ho W, Murphy G. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008 158 : 217.
3. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 348 : 1681.
4. Torres V, Harris P, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007 369 : 1287.
5. Hamer R, Chow C, Ong A, McKane W. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007 83 : 36.
6. Otley C, Cherikh W, Salasche S, McBride M, Christenson L, Kauffman H. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005 53 : 783.
7. Kasiske B, Snyder J, Gilbertson D, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4 : 905.
8. Fitzpatrick T. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988 124 : 869.
9. Martinez JC, Otley C, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients. A multicenter collaborative study. Arch Dermatol 2003 139 : 301.
10. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998 351 : 623.
11. Comeau S, Jensen L, Cockfield SM, Sapijaszko M, Gourishankar S. Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience. Transplantation 2008 86 : 535.
12. Ramsay H, Fryer A, Reece S, Smith A, Harden P. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000 36 : 167.
13. Wimmer C, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007 71 : 1271.
14. Ramsay H, Reece S, Fryer A, Smith A, Harden P. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007 84 : 437.
15. Laing M, Kay E, Conlon P, Murphy G. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol Photoimmunol Photomed 2007 23 : 62.
16. Zheng R, Zhang Z, Lv X, et al. Polycystin-1 induced apoptosis and cell cycle arrest in G0.G1 phase in cancer cells. Cell Biol Int 2008 32 : 427.
17. Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest 1996 98 : 2674.
18. De Mattos A, Olyaei A, Prather J, Golconda M, Barry J, Norman D. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005 67 : 714.
19. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 372 : 449.
20. Wulff B, Kusewitt D, VanBuskirk A, Thomas-Ahner J, Jason D, Oberyszyn T. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008 128 : 2467.
21. Campistol J, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581.
22. Shillingford J, Murcia N, Larson C, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006 103 : 5466.
23. Wahl P, Serra A, Le Hir M, Molle K, Hall M, Wuthrich R. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006 21 : 598.
24. Serra AL, Kistler A, Poster D, et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 2007 8 : 13.